Phlebotomy

TridentCare Expands in the Sunshine State With the Acquisition of Allied Mobile X-Ray & Ultrasound

Retrieved on: 
Tuesday, July 5, 2022
GLOBE, Facebook, Acquisition, Alliance, Growth, Patient, LinkedIn, Phlebotomy, Country, Medical imaging, Healthcare

SPARKS, Md., July 05, 2022 (GLOBE NEWSWIRE) -- TridentCare, a national leader of portable diagnostic services, is excited to announce its acquisition of Allied Mobile X-Ray & Ultrasound.

Key Points: 
  • SPARKS, Md., July 05, 2022 (GLOBE NEWSWIRE) -- TridentCare, a national leader of portable diagnostic services, is excited to announce its acquisition of Allied Mobile X-Ray & Ultrasound.
  • "We're very excited about this acquisition and look forward to welcoming Allied's dedicated team members and loyal customers to the TridentCare family," says TridentCare COO Jeff Hooper.
  • After many years of providing high-quality portable imaging services to its customers, Allied is excited to bring its experienced personnel and know-how to TridentCare.
  • "TridentCare has been the national leader in mobile diagnostics and a reliable, consistent provider throughout the state for many years.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CareDx, Inc. (CDNA)

Retrieved on: 
Tuesday, July 5, 2022
Justice, Defendant, Court, GLOBE, Marketing, Company, Suite, CDNA, U.S. Securities and Exchange Commission, Lists of schools in England, Risk, U.S. Department of Commerce Office of Security, GPM, U.S. Department of Justice Office of Legislative Affairs, NASDAQ, Time, Phlebotomy, News, Physician, Pharmaceutical industry

On this news, the Companys share price fell $19.34, or 27%, to close at $51.00 per share on October 29, 2021, thereby injuring investors.

Key Points: 
  • On this news, the Companys share price fell $19.34, or 27%, to close at $51.00 per share on October 29, 2021, thereby injuring investors.
  • On this news, CareDxs stock fell $2.89, or 8.1%, to close at $32.55 on April 18, 2022, thereby injuring investors further.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

LifeLabs partners with Indspire to commit to providing scholarship opportunities to Indigenous students

Retrieved on: 
Wednesday, June 22, 2022
People, Time, Student, Education, Science, Technology, CEO, OMERS, First Nations, National Indigenous Peoples Day, Indigenous peoples, Phlebotomy, Engineering, SVP, Partnership, History, STEM, GLOBE, Mathematics, Life, Tutoring, Whaling, Medicine, Indigenous, Indspire, Medicine

"We are pleased to recognize this meaningful expression of LifeLabs' ongoing commitment to Indigenous education," said Nicole Desloges, SVP, People of LifeLabs.

Key Points: 
  • "We are pleased to recognize this meaningful expression of LifeLabs' ongoing commitment to Indigenous education," said Nicole Desloges, SVP, People of LifeLabs.
  • "During National Indigenous History Month, it is vital that we recognize the strength, history, and heritage of Indigenous peoples across Canada and invest in the Indigenous leaders of tomorrow."
  • Indspire is excited to partner with LifeLabs, who have made a tangible investment in Indigenous learners by increasing opportunities in a wide breadth of fields, said President and CEO of Indspire Mike DeGagn.
  • In 2020-2021, Indspire provided more than $20 million through 6,245 bursaries and scholarships to First Nations, Inuit, and Mtis students across Canada.

Concorde Career Colleges, Inc. Launches Phlebotomy Technician Program

Retrieved on: 
Wednesday, June 22, 2022
Laboratory, Roger Hawkins (drummer), Vital signs, Nursing, ACCSC, Medical assistant, PCT, CPR, Concorde, COE, CEO, Knowledge, Statistics, Student, Research, Phlebotomy, Hospital, Council on Occupational Education, Council, Program, Occupation, Patient, Employment, Transport, AMCA, Blood, Ministry of Education (Malaysia), Accrediting Commission of Career Schools and Colleges, Medicine

MISSION, Kan., June 22, 2022 /PRNewswire/ -- Concorde Career Colleges, Inc., a national leader in health care education with 17 campuses in eight states, has just announced the addition of a Phlebotomy Technician Diploma Program to help address the widespread shortage of medical technicians. The new program will be available at Concorde's Dallas, Jacksonville, Kansas City, Miramar, Orlando, and Tampa campuses, reaching a large pool of potential students and educating more people about in-demand phlebotomy careers.

Key Points: 
  • MISSION, Kan., June 22, 2022 /PRNewswire/ -- Concorde Career Colleges, Inc., a national leader in health care education with 17 campuses in eight states,has just announced the addition of a Phlebotomy Technician Diploma Program to help address the widespread shortage of medical technicians.
  • Upon program completion, students will have the knowledge to take the Phlebotomy Technician Certification (PCT) exam, given through the American Medical Certification Association (AMCA), with no additional expenses.
  • If graduates from the Phlebotomy Technician Diploma Program choose this education pathway, tuition discount assistance is available.
  • To learn more about the wide variety of health care programs offered at Concorde, please visit www.concorde.edu or call 1-800-280-5231
    Concorde Career Colleges, Inc., which operates 17 campuses in eight states under the brands Concorde Career College and Concorde Career Institute, prepares America's next generation of health care and dental professionals for rewarding careers.

AOP Health Presents Final Results From Its CONTINUATION-PV Study - up to 7.5 Years Treatment With BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera Patients - at EHA 2022 Annual Meeting

Retrieved on: 
Monday, June 20, 2022
Health, Stem Cells, Pharmaceutical, Clinical Trials, Oncology, AOP, EHA, Hematocrit, Hydroxycarbamide, US, Thrombosis, Medical school, Survival, Bone marrow, Disease, Titan IIIB, Quality of life, Health, Death, Ruxolitinib, Group, PV, Solution, Embolism, Interferon, Phlebotomy, BAT, Commonwealth, JAK2, Chronic myelogenous leukemia, European Commission, Product, Royal commission, Commonwealth of Independent States, Critical care, HIV disease progression rates, Leukemia, CIS, Patient, Annual general meeting, Risk, Myeloproliferative neoplasm, Safety, European Hematology Association, Medical University of Vienna, Cancer, Research, CML, ATC, Life, EMA, Goal, Renewable energy, Pharmaceutical industry, Medical device, Ropeginterferon alfa-2b

AOP Health has been conducting a pivotal clinical development program, including the studies PEGINVERA, PROUD-PV and CONTINUATION-PV .

Key Points: 
  • AOP Health has been conducting a pivotal clinical development program, including the studies PEGINVERA, PROUD-PV and CONTINUATION-PV .
  • The results of CONTI-PV after 7.5 years of treatment provide further evidence of the value of BESREMi for patients suffering from PV.
  • 1 Ropeginterferon alpha-2b achieves patient-specific treatment goals in Polycythaemia Vera: final results from the PROUD-PV/CONTINUATION-PV studies.
  • The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (AOP Health).

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of CareDx, Inc. (CDNA) Investors and Encourages Investors to Contact the Firm Before July 22, 2022

Retrieved on: 
Friday, June 17, 2022
Legal, Professional Services, CDNA, LLP, U.S. Department of Defense Strategy for Operating in Cyberspace, Lists of schools in England, Court, Company, Douglas v. U.S. District Court ex rel Talk America, U.S. Securities and Exchange Commission, Phlebotomy, Risk, Physician, Marketing, Kirby, NASDAQ, District court, News, Patient, U.S. Department of Justice Office of Legislative Affairs, Justice, Online gambling, Private investigator

Investors have until July 22, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until July 22, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • The firms efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.
  • Additional information about the firm can be found at Kirby McInerney LLPs website: http://www.kmllp.com .

TridentCare Expands Commercial Presence as Demand for On-Site Occupational Health Increases

Retrieved on: 
Thursday, June 9, 2022
Country, LinkedIn, Industry, Phlebotomy, Growth, GLOBE, Patient, Facebook, COVID-19, Travel, Compliance, Nursing home, Medical imaging, Health insurance

When it comes to employer-sponsored clinics, employers want safe, easily accessible and quality healthcare, while at the same time minimizing risk to the business and its employees.

Key Points: 
  • When it comes to employer-sponsored clinics, employers want safe, easily accessible and quality healthcare, while at the same time minimizing risk to the business and its employees.
  • "We look forward to working with TridentCare, now and into the future," said Anthony Santilli, Chief Executive Officer at Worksite Medical.
  • "With TridentCare's national presence and proven operational know-how for one-stop-shop diagnostics, we can deliver an end-to-end solution to an even wider base of employer customers.
  • For more information about TridentCare, please visit TridentCare.com, and follow us on Facebook and LinkedIn.

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of CareDx, Inc. (CDNA) Investors and Encourages Investors to Contact the Firm Before July 22, 2022

Retrieved on: 
Thursday, June 9, 2022
District court, Company, Marketing, CDNA, Court, Douglas v. U.S. District Court ex rel Talk America, News, U.S. Department of Defense Strategy for Operating in Cyberspace, U.S. Securities and Exchange Commission, Physician, Patient, GLOBE, U.S. Department of Justice Office of Legislative Affairs, Risk, Justice, NASDAQ, Phlebotomy, Lists of schools in England, LLP, Kirby, Online gambling, Private investigator

Investors have until July 22, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until July 22, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • The firms efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CareDx, Inc. (CDNA)

Retrieved on: 
Thursday, June 9, 2022
Time, Company, Marketing, CDNA, Court, News, U.S. Department of Commerce Office of Security, Physician, GLOBE, Justice, U.S. Department of Justice Office of Legislative Affairs, Risk, Defendant, GPM, NASDAQ, Phlebotomy, Lists of schools in England, U.S. Securities and Exchange Commission, Suite, Pharmaceutical industry

On this news, the Companys share price fell $19.34, or 27%, to close at $51.00 per share on October 29, 2021, thereby injuring investors.

Key Points: 
  • On this news, the Companys share price fell $19.34, or 27%, to close at $51.00 per share on October 29, 2021, thereby injuring investors.
  • On this news, CareDxs stock fell $2.89, or 8.1%, to close at $32.55 on April 18, 2022, thereby injuring investors further.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of CareDx, Inc. (CDNA) Investors

Retrieved on: 
Wednesday, June 8, 2022
Legal, Professional Services, District court, Company, Marketing, CDNA, Court, Douglas v. U.S. District Court ex rel Talk America, News, U.S. Department of Defense Strategy for Operating in Cyberspace, U.S. Securities and Exchange Commission, Physician, Patient, Justice, U.S. Department of Justice Office of Legislative Affairs, Risk, NASDAQ, Phlebotomy, Lists of schools in England, LLP, Kirby, Online gambling, Private investigator

Investors have until July 22, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until July 22, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • The firms efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.
  • Additional information about the firm can be found at Kirby McInerney LLPs website: http://www.kmllp.com .